Treatment of pulmonary alveolar microlithiasis with a diphosphonate--preliminary results of a case.
A diphosphonate, disodium etidronate, a compound known to inhibit microcrystal growth of hydroxyapatite was given to a 3.5-year-old girl with pulmonary alveolar microlithiasis (PAM) that was symptomatic. The drug was used for approximately 36 months in a single daily dose of 15 mg/kg. No significant side effects were encountered with somewhat clearing of lung bases in chest radiograms and subjective improvement in general condition. These findings suggest a role of diphosphonates in the treatment of PAM.
Göcmen
A
A
Pediatric Chest Diseases Department, Hacettepe Childrens' Hospital, Ankara, Turkey.
Toppare
M F
MF
Kiper
N
N
Büyükpamukcu
N
N
D002114:Calcinosis / Q000188:drug therapy; D002137:Calculi / Q000188:drug therapy*; D002675:Child, Preschool; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D011650:Pulmonary Alveoli; D012129:Respiratory Function Tests
D012968:Etidronic Acid